aluates Reports

$ 0.0

Automative

Global Onychomycosis Drugs Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-26F1013

Global Onychomycosis Drugs Market Insights and Forecast to 2028

BUY CHAPTERS

Global Onychomycosis Drugs Market Research Report 2025

Code: QYRE-Auto-26F1013

Report

September 2025

Pages:94

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Novartis

Johnson & Johnson

Bausch Health

Bayer

Galderma

Moberg Pharma

Cipla Ltd

Biofrontera

LEO Pharma

Dr. Reddy’s Laboratories

Medimetriks Pharmaceuticals

GSK

Kaken Pharmaceutical

Lumenis Inc

Xiuzheng Pharmaceutical

Letai

Qilu Pharmaceutical

Johnson & Johnson

Onychomycosis Drugs Market Size

The global market for Onychomycosis Drugs was valued at US$ 3525 million in the year 2024 and is projected to reach a revised size of US$ 4439 million by 2031, growing at a CAGR of 3.4% during the forecast period.

Onychomycosis Drugs Market

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Onychomycosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Onychomycosis Drugs.

The Onychomycosis Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Onychomycosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Onychomycosis Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Onychomycosis Drugs Market Report

Report Metric	Details
Report Name	Onychomycosis Drugs Market
Accounted market size in year	US$ 3525 million
Forecasted market size in 2031	US$ 4439 million
CAGR	3.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Oral Medicine External Medicine
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Johnson & Johnson, GSK, Novartis, Pfizer, Bausch Health, Kaken Pharmaceutical, Galderma, Bayer, Lumenis, Moberg Pharma, Cipla, Biofrontera, Leo Pharma, Dr. Reddy's Laboratories, Medimetriks Pharmaceuticals, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Onychomycosis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Onychomycosis Drugs Market growing?

Ans: The Onychomycosis Drugs Market witnessing a CAGR of 3.4% during the forecast period 2025-2031.

What is the Onychomycosis Drugs Market size in 2031?

Ans: The Onychomycosis Drugs Market size in 2031 will be US$ 4439 million.

Who are the main players in the Onychomycosis Drugs Market report?

Ans: The main players in the Onychomycosis Drugs Market are Johnson & Johnson, GSK, Novartis, Pfizer, Bausch Health, Kaken Pharmaceutical, Galderma, Bayer, Lumenis, Moberg Pharma, Cipla, Biofrontera, Leo Pharma, Dr. Reddy's Laboratories, Medimetriks Pharmaceuticals, Xiuzheng Pharmaceutical, Letai, Qilu Pharmaceutical

What are the Application segmentation covered in the Onychomycosis Drugs Market report?

Ans: The Applications covered in the Onychomycosis Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Onychomycosis Drugs Market report?

Ans: The Types covered in the Onychomycosis Drugs Market report are Oral Medicine, External Medicine

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Onychomycosis Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Oral Medicine

1.2.3 External Medicine

1.3 Market by Application

1.3.1 Global Onychomycosis Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Onychomycosis Drugs Market Perspective (2020-2031)

2.2 Global Onychomycosis Drugs Growth Trends by Region

2.2.1 Global Onychomycosis Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Onychomycosis Drugs Historic Market Size by Region (2020-2025)

2.2.3 Onychomycosis Drugs Forecasted Market Size by Region (2026-2031)

2.3 Onychomycosis Drugs Market Dynamics

2.3.1 Onychomycosis Drugs Industry Trends

2.3.2 Onychomycosis Drugs Market Drivers

2.3.3 Onychomycosis Drugs Market Challenges

2.3.4 Onychomycosis Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Onychomycosis Drugs Players by Revenue

3.1.1 Global Top Onychomycosis Drugs Players by Revenue (2020-2025)

3.1.2 Global Onychomycosis Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Onychomycosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Onychomycosis Drugs Revenue

3.4 Global Onychomycosis Drugs Market Concentration Ratio

3.4.1 Global Onychomycosis Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Onychomycosis Drugs Revenue in 2024

3.5 Global Key Players of Onychomycosis Drugs Head office and Area Served

3.6 Global Key Players of Onychomycosis Drugs, Product and Application

3.7 Global Key Players of Onychomycosis Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Onychomycosis Drugs Breakdown Data by Type

4.1 Global Onychomycosis Drugs Historic Market Size by Type (2020-2025)

4.2 Global Onychomycosis Drugs Forecasted Market Size by Type (2026-2031)

5 Onychomycosis Drugs Breakdown Data by Application

5.1 Global Onychomycosis Drugs Historic Market Size by Application (2020-2025)

5.2 Global Onychomycosis Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Onychomycosis Drugs Market Size (2020-2031)

6.2 North America Onychomycosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Onychomycosis Drugs Market Size by Country (2020-2025)

6.4 North America Onychomycosis Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Onychomycosis Drugs Market Size (2020-2031)

7.2 Europe Onychomycosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Onychomycosis Drugs Market Size by Country (2020-2025)

7.4 Europe Onychomycosis Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Onychomycosis Drugs Market Size (2020-2031)

8.2 Asia-Pacific Onychomycosis Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Onychomycosis Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Onychomycosis Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Onychomycosis Drugs Market Size (2020-2031)

9.2 Latin America Onychomycosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Onychomycosis Drugs Market Size by Country (2020-2025)

9.4 Latin America Onychomycosis Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Onychomycosis Drugs Market Size (2020-2031)

10.2 Middle East & Africa Onychomycosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Onychomycosis Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Onychomycosis Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Company Details

11.1.2 Johnson & Johnson Business Overview

11.1.3 Johnson & Johnson Onychomycosis Drugs Introduction

11.1.4 Johnson & Johnson Revenue in Onychomycosis Drugs Business (2020-2025)

11.1.5 Johnson & Johnson Recent Development

11.2 GSK

11.2.1 GSK Company Details

11.2.2 GSK Business Overview

11.2.3 GSK Onychomycosis Drugs Introduction

11.2.4 GSK Revenue in Onychomycosis Drugs Business (2020-2025)

11.2.5 GSK Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Onychomycosis Drugs Introduction

11.3.4 Novartis Revenue in Onychomycosis Drugs Business (2020-2025)

11.3.5 Novartis Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Details

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Onychomycosis Drugs Introduction

11.4.4 Pfizer Revenue in Onychomycosis Drugs Business (2020-2025)

11.4.5 Pfizer Recent Development

11.5 Bausch Health

11.5.1 Bausch Health Company Details

11.5.2 Bausch Health Business Overview

11.5.3 Bausch Health Onychomycosis Drugs Introduction

11.5.4 Bausch Health Revenue in Onychomycosis Drugs Business (2020-2025)

11.5.5 Bausch Health Recent Development

11.6 Kaken Pharmaceutical

11.6.1 Kaken Pharmaceutical Company Details

11.6.2 Kaken Pharmaceutical Business Overview

11.6.3 Kaken Pharmaceutical Onychomycosis Drugs Introduction

11.6.4 Kaken Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025)

11.6.5 Kaken Pharmaceutical Recent Development

11.7 Galderma

11.7.1 Galderma Company Details

11.7.2 Galderma Business Overview

11.7.3 Galderma Onychomycosis Drugs Introduction

11.7.4 Galderma Revenue in Onychomycosis Drugs Business (2020-2025)

11.7.5 Galderma Recent Development

11.8 Bayer

11.8.1 Bayer Company Details

11.8.2 Bayer Business Overview

11.8.3 Bayer Onychomycosis Drugs Introduction

11.8.4 Bayer Revenue in Onychomycosis Drugs Business (2020-2025)

11.8.5 Bayer Recent Development

11.9 Lumenis

11.9.1 Lumenis Company Details

11.9.2 Lumenis Business Overview

11.9.3 Lumenis Onychomycosis Drugs Introduction

11.9.4 Lumenis Revenue in Onychomycosis Drugs Business (2020-2025)

11.9.5 Lumenis Recent Development

11.10 Moberg Pharma

11.10.1 Moberg Pharma Company Details

11.10.2 Moberg Pharma Business Overview

11.10.3 Moberg Pharma Onychomycosis Drugs Introduction

11.10.4 Moberg Pharma Revenue in Onychomycosis Drugs Business (2020-2025)

11.10.5 Moberg Pharma Recent Development

11.11 Cipla

11.11.1 Cipla Company Details

11.11.2 Cipla Business Overview

11.11.3 Cipla Onychomycosis Drugs Introduction

11.11.4 Cipla Revenue in Onychomycosis Drugs Business (2020-2025)

11.11.5 Cipla Recent Development

11.12 Biofrontera

11.12.1 Biofrontera Company Details

11.12.2 Biofrontera Business Overview

11.12.3 Biofrontera Onychomycosis Drugs Introduction

11.12.4 Biofrontera Revenue in Onychomycosis Drugs Business (2020-2025)

11.12.5 Biofrontera Recent Development

11.13 Leo Pharma

11.13.1 Leo Pharma Company Details

11.13.2 Leo Pharma Business Overview

11.13.3 Leo Pharma Onychomycosis Drugs Introduction

11.13.4 Leo Pharma Revenue in Onychomycosis Drugs Business (2020-2025)

11.13.5 Leo Pharma Recent Development

11.14 Dr. Reddy's Laboratories

11.14.1 Dr. Reddy's Laboratories Company Details

11.14.2 Dr. Reddy's Laboratories Business Overview

11.14.3 Dr. Reddy's Laboratories Onychomycosis Drugs Introduction

11.14.4 Dr. Reddy's Laboratories Revenue in Onychomycosis Drugs Business (2020-2025)

11.14.5 Dr. Reddy's Laboratories Recent Development

11.15 Medimetriks Pharmaceuticals

11.15.1 Medimetriks Pharmaceuticals Company Details

11.15.2 Medimetriks Pharmaceuticals Business Overview

11.15.3 Medimetriks Pharmaceuticals Onychomycosis Drugs Introduction

11.15.4 Medimetriks Pharmaceuticals Revenue in Onychomycosis Drugs Business (2020-2025)

11.15.5 Medimetriks Pharmaceuticals Recent Development

11.16 Xiuzheng Pharmaceutical

11.16.1 Xiuzheng Pharmaceutical Company Details

11.16.2 Xiuzheng Pharmaceutical Business Overview

11.16.3 Xiuzheng Pharmaceutical Onychomycosis Drugs Introduction

11.16.4 Xiuzheng Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025)

11.16.5 Xiuzheng Pharmaceutical Recent Development

11.17 Letai

11.17.1 Letai Company Details

11.17.2 Letai Business Overview

11.17.3 Letai Onychomycosis Drugs Introduction

11.17.4 Letai Revenue in Onychomycosis Drugs Business (2020-2025)

11.17.5 Letai Recent Development

11.18 Qilu Pharmaceutical

11.18.1 Qilu Pharmaceutical Company Details

11.18.2 Qilu Pharmaceutical Business Overview

11.18.3 Qilu Pharmaceutical Onychomycosis Drugs Introduction

11.18.4 Qilu Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025)

11.18.5 Qilu Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Novartis

Johnson & Johnson

Bausch Health

Bayer

Galderma

Moberg Pharma

Cipla Ltd

Biofrontera

LEO Pharma

Dr. Reddy’s Laboratories

Medimetriks Pharmaceuticals

GSK

Kaken Pharmaceutical

Lumenis Inc

Xiuzheng Pharmaceutical

Letai

Qilu Pharmaceutical

Johnson & Johnson

List of Tables

Table 1. Global Onychomycosis Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Oral Medicine

Table 3. Key Players of External Medicine

Table 4. Global Onychomycosis Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Onychomycosis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Onychomycosis Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Onychomycosis Drugs Market Share by Region (2020-2025)

Table 8. Global Onychomycosis Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Onychomycosis Drugs Market Share by Region (2026-2031)

Table 10. Onychomycosis Drugs Market Trends

Table 11. Onychomycosis Drugs Market Drivers

Table 12. Onychomycosis Drugs Market Challenges

Table 13. Onychomycosis Drugs Market Restraints

Table 14. Global Onychomycosis Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Onychomycosis Drugs Market Share by Players (2020-2025)

Table 16. Global Top Onychomycosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis Drugs as of 2024)

Table 17. Ranking of Global Top Onychomycosis Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Onychomycosis Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Onychomycosis Drugs, Headquarters and Area Served

Table 20. Global Key Players of Onychomycosis Drugs, Product and Application

Table 21. Global Key Players of Onychomycosis Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Onychomycosis Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Onychomycosis Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Onychomycosis Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Onychomycosis Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Onychomycosis Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Onychomycosis Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Onychomycosis Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Onychomycosis Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Onychomycosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Onychomycosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Onychomycosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Onychomycosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Onychomycosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Onychomycosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Onychomycosis Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Onychomycosis Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Onychomycosis Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Onychomycosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Onychomycosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Onychomycosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Onychomycosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Onychomycosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Onychomycosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Johnson & Johnson Company Details

Table 47. Johnson & Johnson Business Overview

Table 48. Johnson & Johnson Onychomycosis Drugs Product

Table 49. Johnson & Johnson Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 50. Johnson & Johnson Recent Development

Table 51. GSK Company Details

Table 52. GSK Business Overview

Table 53. GSK Onychomycosis Drugs Product

Table 54. GSK Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 55. GSK Recent Development

Table 56. Novartis Company Details

Table 57. Novartis Business Overview

Table 58. Novartis Onychomycosis Drugs Product

Table 59. Novartis Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 60. Novartis Recent Development

Table 61. Pfizer Company Details

Table 62. Pfizer Business Overview

Table 63. Pfizer Onychomycosis Drugs Product

Table 64. Pfizer Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 65. Pfizer Recent Development

Table 66. Bausch Health Company Details

Table 67. Bausch Health Business Overview

Table 68. Bausch Health Onychomycosis Drugs Product

Table 69. Bausch Health Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 70. Bausch Health Recent Development

Table 71. Kaken Pharmaceutical Company Details

Table 72. Kaken Pharmaceutical Business Overview

Table 73. Kaken Pharmaceutical Onychomycosis Drugs Product

Table 74. Kaken Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 75. Kaken Pharmaceutical Recent Development

Table 76. Galderma Company Details

Table 77. Galderma Business Overview

Table 78. Galderma Onychomycosis Drugs Product

Table 79. Galderma Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 80. Galderma Recent Development

Table 81. Bayer Company Details

Table 82. Bayer Business Overview

Table 83. Bayer Onychomycosis Drugs Product

Table 84. Bayer Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 85. Bayer Recent Development

Table 86. Lumenis Company Details

Table 87. Lumenis Business Overview

Table 88. Lumenis Onychomycosis Drugs Product

Table 89. Lumenis Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 90. Lumenis Recent Development

Table 91. Moberg Pharma Company Details

Table 92. Moberg Pharma Business Overview

Table 93. Moberg Pharma Onychomycosis Drugs Product

Table 94. Moberg Pharma Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 95. Moberg Pharma Recent Development

Table 96. Cipla Company Details

Table 97. Cipla Business Overview

Table 98. Cipla Onychomycosis Drugs Product

Table 99. Cipla Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 100. Cipla Recent Development

Table 101. Biofrontera Company Details

Table 102. Biofrontera Business Overview

Table 103. Biofrontera Onychomycosis Drugs Product

Table 104. Biofrontera Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 105. Biofrontera Recent Development

Table 106. Leo Pharma Company Details

Table 107. Leo Pharma Business Overview

Table 108. Leo Pharma Onychomycosis Drugs Product

Table 109. Leo Pharma Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 110. Leo Pharma Recent Development

Table 111. Dr. Reddy's Laboratories Company Details

Table 112. Dr. Reddy's Laboratories Business Overview

Table 113. Dr. Reddy's Laboratories Onychomycosis Drugs Product

Table 114. Dr. Reddy's Laboratories Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 115. Dr. Reddy's Laboratories Recent Development

Table 116. Medimetriks Pharmaceuticals Company Details

Table 117. Medimetriks Pharmaceuticals Business Overview

Table 118. Medimetriks Pharmaceuticals Onychomycosis Drugs Product

Table 119. Medimetriks Pharmaceuticals Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 120. Medimetriks Pharmaceuticals Recent Development

Table 121. Xiuzheng Pharmaceutical Company Details

Table 122. Xiuzheng Pharmaceutical Business Overview

Table 123. Xiuzheng Pharmaceutical Onychomycosis Drugs Product

Table 124. Xiuzheng Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 125. Xiuzheng Pharmaceutical Recent Development

Table 126. Letai Company Details

Table 127. Letai Business Overview

Table 128. Letai Onychomycosis Drugs Product

Table 129. Letai Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 130. Letai Recent Development

Table 131. Qilu Pharmaceutical Company Details

Table 132. Qilu Pharmaceutical Business Overview

Table 133. Qilu Pharmaceutical Onychomycosis Drugs Product

Table 134. Qilu Pharmaceutical Revenue in Onychomycosis Drugs Business (2020-2025) & (US$ Million)

Table 135. Qilu Pharmaceutical Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

Table 139. Authors List of This Report

List of Figures

Figure 1. Onychomycosis Drugs Picture

Figure 2. Global Onychomycosis Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Onychomycosis Drugs Market Share by Type: 2024 VS 2031

Figure 4. Oral Medicine Features

Figure 5. External Medicine Features

Figure 6. Global Onychomycosis Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Onychomycosis Drugs Market Share by Application: 2024 VS 2031

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Online Pharmacies Case Studies

Figure 11. Onychomycosis Drugs Report Years Considered

Figure 12. Global Onychomycosis Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Onychomycosis Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Onychomycosis Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Onychomycosis Drugs Market Share by Players in 2024

Figure 16. Global Top Onychomycosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Onychomycosis Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Onychomycosis Drugs Revenue in 2024

Figure 18. North America Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Onychomycosis Drugs Market Share by Country (2020-2031)

Figure 20. United States Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Onychomycosis Drugs Market Share by Country (2020-2031)

Figure 24. Germany Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Onychomycosis Drugs Market Share by Region (2020-2031)

Figure 32. China Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Onychomycosis Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Onychomycosis Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Onychomycosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Johnson & Johnson Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 48. GSK Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 49. Novartis Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 50. Pfizer Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 51. Bausch Health Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 52. Kaken Pharmaceutical Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 53. Galderma Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 54. Bayer Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 55. Lumenis Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 56. Moberg Pharma Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 57. Cipla Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 58. Biofrontera Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 59. Leo Pharma Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 60. Dr. Reddy's Laboratories Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 61. Medimetriks Pharmaceuticals Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 62. Xiuzheng Pharmaceutical Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 63. Letai Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 64. Qilu Pharmaceutical Revenue Growth Rate in Onychomycosis Drugs Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Onychomycosis Treatment Market Research Report 2024

Global Dermatophytic Onychomycosis Therapeutics DOT Market Research Report 2024

Global Fungal Drugs for Treatment of Tinea Market Research Report 2025

Global Tinea Corporis Drugs Market Research Report 2024

Drugs for Dermatophytosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Fungal Nail Infections Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Onychomycosis Therapy Market Research Report 2024

Dermatophytosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Tinea Corporis Treatment Market Research Report 2025

Dermatophytosis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ringworm Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anti fungal Drugs Market Insights Forecast to 2030

Global Onychomycosis Treatment Technique Market Research Report 2024

Global Fungal Foot Drugs Market Insights Forecast to 2030

Global Anti Dermatomycosis Treatment Market Research Report 2025

Dermatophytosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Human Tinea Pedis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antifungal Drugs for Skin Market Research Report 2024

Treatmet of Dermatophytosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions